Acurx Pharmaceuticals, Inc.
ACXP
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.54M | 6.05M | 6.26M | 6.89M | 6.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.67M | 7.63M | 8.09M | 9.27M | 10.07M |
| Operating Income | -7.67M | -7.63M | -8.09M | -9.27M | -10.07M |
| Income Before Tax | -7.51M | -7.50M | -7.97M | -9.17M | -10.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.51 | -7.50 | -7.97 | -9.17 | -10.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.51M | -7.50M | -7.97M | -9.17M | -10.00M |
| EBIT | -7.67M | -7.63M | -8.09M | -9.27M | -10.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.10 | -4.46 | -5.99 | -8.54 | -10.77 |
| Normalized Basic EPS | -1.94 | -2.79 | -3.74 | -5.34 | -6.73 |
| EPS Diluted | -3.10 | -4.46 | -5.99 | -8.54 | -10.77 |
| Normalized Diluted EPS | -1.94 | -2.79 | -3.74 | -5.34 | -6.73 |
| Average Basic Shares Outstanding | 10.77M | 7.70M | 5.99M | 4.66M | 3.86M |
| Average Diluted Shares Outstanding | 10.77M | 7.70M | 5.99M | 4.66M | 3.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |